Definium Therapeutics Prices $700 Million Upsized Public Offering on June 24, 2026 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene commercialization Definium Therapeutics development aspects DFTX DT120 ODT Jefferies Leerink Partners public entity research securities working capital +
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement on June 18, 2026 Alvotech biosimilar medicines Concurrent development aspects Options private placement public entity research underwriters working capital +